Table 3

Promter Hypermethylation and cervical cancer survival

Alive

Dead

Hazard Ratio§

95%CI


Total loci

0

9

2

1.00

1

6

9

0.75

0.14–4.00

2

13

19

1.04

0.20–5.50

≥3

11

13

1.07

0.19–5.92

CDH1

+

18

27

0.69

0.29–1.63

-

21

16

1.00

DAPK

+

19

18

0.53

0.23–1.19

-

20

25

1.00

RARB

+

8

16

1.66

0.80–3.46

-

31

27

1.00

HIC1

+

7

8

1.67

0.69–4.04

-

32

35

1.00

FHIT

+

3

6

1.18

0.38–3.66

-

36

37

1.00

RASSF1A

+

5

1

2.02

0.16–25.08

-

34

42

1.00

APC

+

4

5

0.70

0.21–2.41

-

35

38

1.00

CDKN2A

+

2

5

1.64

0.51–5.26

-

37

38

1.00

MGMT

+

0

4

2.30

0.46–11.45

-

39

39

1.00

BRCA1

+

0

5

3.05

0.72–12.93

-

39

38

1.00


Adjusted for age (continuous), treatment (3 groups), tumor size (binary), stage (3 groups) and HPV type (4 groups)

Narayan et al. Molecular Cancer 2003 2:24   doi:10.1186/1476-4598-2-24

Open Data